Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.
Genetic variation in the cholinergic muscarinic-2 (M(2)) receptor gene (CHRM2) has been associated with the risk for developing depression. We previously reported that M(2)-receptor distribution volume (V(T)) was reduced in depressed subjects with bipolar disorder (BD) relative to depressed subjects with major depressive disorder (MDD) and healthy controls (HCs). In this study, we investigated the effects of six single-nucleotide polymorphisms (SNPs) for CHRM2 on M(2)-receptor binding to test the hypotheses that genetic variation in CHRM2 influences M(2)-receptor binding and that a CHRM2 polymorphism underlies the deficits in M(2)-receptor V(T) observed in BD. The M(2)-receptor V(T) was measured using positron emission tomography and [(18)F]FP-TZTP in unmedicated, depressed subjects with BD (n=16) or MDD (n=24) and HCs (n=25), and the effect of genotype on V(T) was assessed. In the controls, one SNP (with identifier rs324650, in which the ancestral allele adenine (A) is replaced with one or two copies of thymine (T), showed a significant allelic effect on V(T) in the pregenual and subgenual anterior cingulate cortices in the direction AA<AT<TT. In contrast, in BD subjects with the TT genotype, V(T) was significantly lower than in BD subjects with the AT genotype in these regions. The BD subjects homozygous for the T -allele also showed markedly lower V(T) (by 27 to 37% across regions) than HCs of the same genotype. Post hoc analyses suggested that T homozygosity was associated with a more severe illness course, as manifested by lower socioeconomic function, poorer spatial recognition memory and a greater likelihood of having attempted suicide. These data represent novel preliminary evidence that reduced M(2)-receptor V(T) in BD is associated with genetic variation within CHRM2. The differential impact of the M(2)-receptor polymorphism at rs324650 in the BD and HC samples suggests interactive effects with an unidentified vulnerability factor for BD.
Cannon
D M
DM
Clinical Neuroimaging Laboratory, Department of Psychiatry, National University of Ireland, Galway, Co. Galway, Ireland. dara.cannon@nuigalway.ie
Klaver
J K
JK
Gandhi
S K
SK
Solorio
G
G
Peck
S A
SA
Erickson
K
K
Akula
N
N
Savitz
J
J
Eckelman
W C
WC
Furey
M L
ML
Sahakian
B J
BJ
McMahon
F J
FJ
Drevets
W C
WC
D000293:Adolescent; D000328:Adult; D001714:Bipolar Disorder / Q000150:complications / Q000000981:diagnostic imaging / Q000235:genetics*; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism*; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology; D005260:Female; D005462:Fluorine Radioisotopes; D055106:Genome-Wide Association Study; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D049268:Positron-Emission Tomography / Q000379:methods; D011485:Protein Binding / Q000187:drug effects / Q000235:genetics; D011569:Psychiatric Status Rating Scales; D043585:Receptor, Muscarinic M2 / Q000235:genetics* / Q000378:metabolism*; D018709:Statistics, Nonparametric; D055815:Young Adult
C487078:CHRM2 protein, human; D005462:Fluorine Radioisotopes; D043585:Receptor, Muscarinic M2